How to Get Addyi in Wisconsin: Prescriptions, Telehealth, and Pharmacies

What Is Flibanserin and Why Does It Require a Special Prescribing Process?

Flibanserin is the only FDA-approved non-hormonal treatment for HSDD in premenopausal women. The FDA approved it in August 2015 under the brand name Addyi after two earlier complete-response letters were resolved partly through a patient advocacy campaign. Because flibanserin carries a boxed warning for severe hypotension and syncope when combined with alcohol or CYP3A4 inhibitors, the FDA requires enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program before any prescriber can write the medication or any pharmacy can dispense it. [1, 2]

HSDD itself is defined as persistent or recurrent deficiency of sexual desire that causes marked distress or interpersonal difficulty and is not better explained by a medical condition, relationship problem, or the effects of another drug. [3] The condition is more common than many clinicians recognize. One population-based survey estimated that 8.9% of premenopausal women in the United States meet diagnostic criteria for HSDD with associated distress. [4]

The REMS requirement means you cannot simply call any doctor or walk into any pharmacy. Every step of the Wisconsin access pathway involves confirming that the prescriber is enrolled in the Addyi REMS program and, if you use a compounding pharmacy, that the pharmacy holds appropriate state licensure.

How HSDD Is Diagnosed Before a Prescription Can Be Written

A Wisconsin prescriber must establish a formal diagnosis of HSDD before writing for flibanserin. No validated blood panel diagnoses HSDD. The diagnosis is clinical, based on a structured interview and validated patient-reported outcome tools. [5]

The most widely used screening instrument is the Female Sexual Function Index (FSFI), a 19-item self-administered questionnaire that generates domain scores for desire, arousal, lubrication, orgasm, satisfaction, and pain. An FSFI total score below 26.55 suggests female sexual dysfunction; the desire sub-score specifically captures the HSDD dimension. The Female Sexual Distress Scale-Revised (FSDS-R) is then used to confirm that low desire is causing distress, which is required for the HSDD diagnosis. [5, 6]

Your prescriber will also rule out secondary causes before diagnosing HSDD: thyroid dysfunction, depression, hyperprolactinemia, and relationship stressors all require exclusion. [7] Antidepressants, antihistamines, hormonal contraceptives, and antihypertensives can each suppress desire independently. A thorough medication review is part of every legitimate HSDD evaluation. [8]

Labs Required Before Starting Addyi in Wisconsin

No labs diagnose HSDD, but several tests rule out treatable causes of low desire and establish a safety baseline before prescribing flibanserin. Most Wisconsin prescribers order the following panel at or before the first visit.

Thyroid-stimulating hormone (TSH). Hypothyroidism frequently presents with low libido, fatigue, and mood changes. Treating the underlying thyroid disorder often resolves desire complaints without flibanserin. The American Thyroid Association recommends TSH as the first-line screening test for thyroid dysfunction. [9]

Prolactin. Hyperprolactinemia suppresses gonadotropin-releasing hormone, lowering estrogen and testosterone. A fasting prolactin level rules this out before attributing low desire to HSDD. [7]

Total and free testosterone. While no testosterone threshold defines HSDD, low circulating androgen levels may contribute to low desire, and some clinicians use the result to guide adjunctive therapy or to rule out a treatable androgen deficiency. [10]

Comprehensive metabolic panel (CMP). Flibanserin is metabolized primarily by CYP3A4 and undergoes hepatic clearance. The FDA label contraindicates flibanserin in patients with hepatic impairment. A baseline CMP confirms adequate liver function. [1]

Pregnancy test. Flibanserin has not been studied in pregnancy. A urine or serum human chorionic gonadotropin confirms premenopausal, non-pregnant status before the first prescription. [1]

Some Wisconsin telehealth platforms offer at-home lab kits that can be ordered at the time of scheduling, so results are available before the prescriber visit and avoid delays.

Who Can Prescribe Addyi in Wisconsin

Wisconsin law permits any licensed practitioner with prescriptive authority to prescribe Schedule IV and non-scheduled prescription drugs, provided they hold appropriate DEA registration where required. Flibanserin is not a scheduled substance, so no DEA registration is needed specifically for Addyi. [11] The binding requirement is REMS enrollment through Sprout Pharmaceuticals, not a specific prescriber credential.

Physicians (MD and DO). Board-certified OB/GYNs, family medicine physicians, and internists are the most common prescribers of flibanserin. The North American Menopause Society (NAMS) clinical practice statement on HSDD notes that any trained clinician comfortable with sexual medicine can manage flibanserin. [12]

Nurse practitioners (NPs). Wisconsin grants full practice authority to certified nurse practitioners under Wis. Stat. section 441.16. NPs can diagnose, treat, and prescribe independently without a physician collaborating agreement, which makes NP-led telehealth platforms particularly efficient for HSDD care. [13]

Physician assistants (PAs). Wisconsin PAs practice under a collaboration agreement with a physician, but the agreement does not restrict which drug classes the PA may prescribe, so PA-authored flibanserin prescriptions are legally valid in Wisconsin. [14]

Telehealth Access to Addyi in Wisconsin

Wisconsin explicitly permits telehealth prescribing of flibanserin. Prescribers must conduct a synchronous audio-video evaluation that meets the standard of care for an in-person visit, including the diagnostic interview and FSFI/FSDS-R administration. Audio-only encounters are generally not sufficient to establish a new diagnosis of HSDD for prescribing purposes. [15]

The Wisconsin Medical Examining Board and the telehealth provisions under Wis. Stat. section 448.9725 require that any prescriber practicing telehealth to Wisconsin patients must either hold a Wisconsin license or qualify for an interstate compact exemption. Several states participate in the Interstate Medical Licensure Compact (IMLC) and the Nurse Licensure Compact (NLC), allowing out-of-state clinicians to serve Wisconsin patients lawfully. [16]

Practically, a telehealth appointment for HSDD follows this sequence. First, the patient completes intake forms and validated questionnaires online before the visit. Second, the prescriber conducts a 20-to-40-minute video consultation that covers sexual history, relationship factors, medication review, and medical history. Third, if HSDD is confirmed, the prescriber sends the prescription electronically to an Addyi REMS-certified pharmacy. Fourth, the pharmacy verifies REMS enrollment, counsels the patient about the alcohol restriction, and ships or dispenses the medication.

Many patients in Wisconsin complete this entire pathway without leaving home, with lab kits mailed to them and prescriptions shipped to their door.

Where to Fill an Addyi Prescription in Wisconsin

Retail Pharmacies

Not every retail pharmacy carries flibanserin in stock, but any REMS-certified retail pharmacy in Wisconsin can order and dispense it. Large chains including Walgreens, CVS, and Walmart have REMS-certified locations throughout the state. Call ahead to confirm stock or ask your prescriber to send the prescription to a pharmacy that routinely stocks flibanserin.

503A Compounding Pharmacies

Wisconsin-licensed 503A compounding pharmacies can legally prepare flibanserin in alternative dosage forms or concentrations, provided the pharmacy holds a valid Wisconsin Pharmacy Examining Board license and complies with USP Chapter 795 standards. [17] Compounded flibanserin is not bioequivalent-tested against brand Addyi, and the FDA has not evaluated compounded preparations for efficacy or safety. Patients who use a 503A compound must still complete the REMS patient-prescriber agreement, and the prescribing clinician assumes responsibility for the compounded formulation.

Compounding is most commonly requested by patients who have documented allergies to excipients in the commercial tablet, who want a liquid formulation for swallowing difficulties, or who face cost barriers to the brand product.

Mail-Order and Specialty Pharmacy Options

Several specialty pharmacies that operate nationally can ship to Wisconsin addresses. Shipping a controlled substance across state lines is federally regulated, but flibanserin is not scheduled, so mail-order shipment is legal without additional DEA documentation. Specialty pharmacies often negotiate manufacturer rebates that reduce out-of-pocket cost below what local pharmacies can offer.

Wisconsin Medicaid Coverage and Prior Authorization

Wisconsin ForwardHealth (Medicaid) covers flibanserin for premenopausal women with a documented diagnosis of HSDD, but requires prior authorization in every case. [18] The prior authorization process requires the prescriber to submit evidence that the diagnosis was established using validated tools, that secondary causes of low desire were evaluated and ruled out or addressed, and that the patient was counseled on the alcohol restriction before the first dose.

Documentation commonly requested during the PA process includes the FSFI and FSDS-R scores, a medication reconciliation confirming no concurrent CYP3A4 inhibitors, a recent TSH and prolactin result, and a clinical note confirming premenopausal status. Submitting a complete chart at the first PA request dramatically reduces the 10-to-14-business-day review timeline.

For patients with commercial insurance, coverage varies by plan. The Addyi manufacturer, Sprout Pharmaceuticals, offers a savings card program that reduces out-of-pocket cost to as low as $99 per month for commercially insured patients and offers a free 30-day trial for eligible women. Patients without any insurance can access the drug for approximately $800-$900 per month at list price, though specialty pharmacy negotiation often brings this lower.

The REMS Patient Agreement: What Wisconsin Patients Sign

Before dispensing flibanserin, the pharmacy must provide and the patient must sign (or electronically confirm) the REMS patient-prescriber agreement. The agreement documents that the patient has been counseled on four key points: the absolute alcohol restriction, the prohibition of moderate-to-strong CYP3A4 inhibitors (including fluconazole, ketoconazole, and certain HIV protease inhibitors), the 2-to-4-week onset window before meaningful effect is expected, and the instruction to take the tablet at bedtime only. [1, 2]

The clinical evidence for the alcohol interaction is direct. A pharmacokinetic study embedded in the REMS development showed that women who consumed alcohol within two hours before or six hours after a 100 mg flibanserin dose had a mean minimum blood pressure of 85/60 mmHg and some experienced syncope. [1] This is the pharmacodynamic basis of the boxed warning.

Clinical Evidence Supporting Flibanserin Prescribing

The key evidence for flibanserin comes primarily from three Phase III randomized controlled trials and the integrated analysis published in the Journal of Sexual Medicine. The BEGONIA trial (N=1,378) randomized premenopausal women with HSDD to flibanserin 100 mg nightly versus placebo for 24 weeks. Women in the flibanserin group reported a statistically significant increase in the number of satisfying sexual events (SSEs) per month compared with placebo, and the FSDS-R item 13 distress score improved meaningfully in the treatment arm (P<0.001). [19]

Across the three Phase III trials analyzed together, flibanserin produced an increase of approximately 0.5 to 1.0 additional SSE per month over placebo, a modest but statistically significant and patient-meaningful difference in a population with a low baseline SSE rate of two to three per month. [19, 20]

The 2014 BEGONIA publication specifically cited a number-needed-to-treat for meaningful improvement in desire of approximately 8 to 10, comparable to NNTs seen with phosphodiesterase-5 inhibitors for erectile dysfunction in men. [19] The North American Menopause Society stated in its 2022 position statement that flibanserin is an appropriate option for premenopausal women with HSDD when non-pharmacological approaches have not provided adequate relief. [12]

The HealthRX clinical team uses a three-step triage for Wisconsin patients requesting flibanserin. Step one confirms premenopausal status and excludes contraindications (hepatic impairment, concurrent CYP3A4 inhibitors, current alcohol use disorder). Step two confirms the HSDD diagnosis with FSFI desire sub-score below 3.3 and FSDS-R item 13 score of 3 or higher. Step three identifies the insurance pathway and selects the optimal pharmacy channel (retail REMS, 503A compound, or specialty mail-order) before the prescription is sent, reducing fill delays to under 48 hours in most cases.

Transferring an Existing Addyi Prescription to Wisconsin

Patients who relocate to Wisconsin or who want to transfer their flibanserin prescription to a Wisconsin pharmacy face a straightforward process. Flibanserin is not a controlled substance, so Wisconsin law does not restrict the number of refills that can be transferred or the number of times a prescription can be moved between pharmacies. [11]

The transferring pharmacy calls or electronically contacts the receiving Wisconsin pharmacy and transmits the remaining refill information. If the original prescription was written by an out-of-state prescriber who does not hold a Wisconsin license, the prescription remains valid for dispensing because the prescription was valid where written, but future refills may require a Wisconsin-licensed prescriber once the original script expires. Telehealth platforms that hold Wisconsin licenses can conduct a brief follow-up visit to issue a new Wisconsin prescription with minimal disruption to therapy.

Avoiding Common Delays in the Wisconsin Access Pathway

Several avoidable bottlenecks slow access for Wisconsin patients.

Choosing a prescriber not enrolled in the Addyi REMS is the most common delay. Confirm REMS enrollment before scheduling by asking the prescriber's office directly or by contacting Sprout Pharmaceuticals' REMS line.

Sending the prescription to a pharmacy without flibanserin in stock adds two to five business days for ordering. Specialty pharmacies that stock flibanserin routinely eliminate this delay.

Submitting an incomplete prior authorization for Wisconsin Medicaid is the single largest source of delay for insured patients. Attach the FSFI score sheet, the FSDS-R, the lab results, and the prescriber's clinical note to the PA request on the first submission.

Alcohol use documentation is sometimes overlooked. The REMS requires that the prescriber document the alcohol counseling in the chart. Some insurance reviewers request this documentation during PA. [1, 2]

Safety Monitoring During Ongoing Flibanserin Therapy in Wisconsin

After the initial prescription is filled, ongoing monitoring is straightforward. No mandatory lab schedule exists for flibanserin the way one exists for, say, isotretinoin or clozapine. The FDA label recommends reassessing response at eight weeks. [1] If a patient has not experienced at least a modest improvement in SSEs or desire scores by eight weeks, the benefit-risk balance shifts and discontinuation is appropriate.

Clinicians should revisit the medication list at every refill visit. New prescriptions for fluconazole (used for vaginal candidiasis, a common co-prescription in women of reproductive age), clarithromycin, or any HIV protease inhibitor require temporary flibanserin discontinuation or dose adjustment because these drugs inhibit CYP3A4 and can raise flibanserin plasma levels four-fold or more. [1, 8]

Blood pressure does not require routine monitoring unless the patient develops symptoms of hypotension. Patients should be advised to sit or lie down if they feel dizzy or faint, and to call their prescriber if hypotension symptoms occur repeatedly.

Discontinuation does not require tapering. Flibanserin can be stopped abruptly without withdrawal effects. [1]